Guardant Health Inc. said it will appeal a Delaware court ruling that defined products subject to potential royalty payments stemming from a patent dispute concluded in 2023.
The U.S. District Court for the District of Delaware issued an order limiting the scope of covered products to those existing at the time of the trial, excluding the current versions of Guardant’s Shield and Reveal liquid biopsy tests. The company, based in Palo Alto, California, added that it has validated design modifications to its Guardant360 product and related services to avoid potential ongoing royalty obligations.
Execution of the final judgment and any royalty collection has been stayed pending the appeal process. The dispute centers on intellectual property claims filed by TwinStrand Biosciences Inc. and the University of Washington. Both patents involved in the case have been preliminarily invalidated in ongoing challenges before the U.S. Patent and Trademark Office, and Guardant is separately pursuing appeals before the U.S. Court of Appeals for the Federal Circuit.
Guardant Health develops blood and tissue tests for cancer detection and treatment selection. The company was founded in 2012 and listed on the NASDAQ under the ticker GH.
John Saia, Chief Legal Officer at Guardant Health, stated the company strongly disagrees with the decision and plans to promptly appeal for its overturn. He added that the company has full confidence in the merits of its intellectual property and research and development, expecting to prevail on appeal.
